{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:37:25Z","timestamp":1792683445175,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Among various lupus renal vascular changes, thrombotic microangiopathy (TMA) presented with the most severe clinical manifestations and high mortality. The pathogenesis of TMA in systemic lupus erythematosus (SLE) was complicated. The aim of this study was to assess clinical manifestations, laboratory characteristics, pathological features and risk factors for clinical outcomes of lupus nephritis patients co-existing with renal TMA in a large cohort in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical and renal histopathological data of 148 patients with biopsy-proven lupus nephritis were retrospectively analyzed. Serum complement factor H, A Disintegrin and Metalloprotease with Thrombospondin type I repeats 13 (ADAMTS-13) activity, antiphospholipid antibodies and C4d deposition on renal vessels were further detected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the 148 patients with lupus nephritis, 36 patients were diagnosed as co-existing with renal TMA based on pathological diagnosis. Among the 36 TMA patients, their clinical diagnoses of renal TMA were as followings: 2 patients combining with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 2 patients combining with anti-phospholipid syndrome, 2 patients with malignant hypertension, 1 patient with scleroderma and the other 29 patients presenting with isolated renal TMA. Compared with the non-renal TMA group, patients with renal TMA had significantly higher urine protein (7.09 \u00b1 4.64 vs. 4.75 \u00b1 3.13 g\/24h,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.007) and serum creatinine (159, 86 to 215 vs. 81, 68 to 112 \u03bcmol\/l,\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), higher scores of total activity indices (AI) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), endocapillary hypercellularity (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001), subendothelial hyaline deposits (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003), interstitial inflammation (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005), glomerular leukocyte infiltration (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006), total chronicity indices (CI) (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.033), tubular atrophy (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004) and interstitial fibrosis (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.018). Patients with renal TMA presented with poorer renal outcome (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005) compared with the non-TMA group. Renal TMA (hazard ratio (HR): 2.772, 95% confidence interval: 1.009 to 7.617,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.048) was an independent risk factor for renal outcome in patients with lupus nephritis. The renal outcome was poorer for those with both C4d deposition and decreased serum complement factor H in the TMA group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There were various causes of renal TMA in lupus nephritis. Complement over-activation via both classical and alternative pathways might play an important role in the pathogenesis of renal TMA in lupus nephritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/ar4142","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T10:43:53Z","timestamp":1358246633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":208,"title":["The spectrum of renal thrombotic microangiopathy in lupus nephritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Di","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"3878_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1681\/ASN.V102413","volume":"10","author":"JS Cameron","year":"1999","unstructured":"Cameron JS: Lupus nephritis. J Am Soc Nephrol. 1999, 10: 413-424.","journal-title":"J Am Soc Nephrol"},{"key":"3878_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0272-6386(12)80885-7","volume":"18","author":"G Banfi","year":"1991","unstructured":"Banfi G, Bertani T, Boeri V, Faraggiana T, Mazzucco G, Monga G, Sacchi G: Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis. 1991, 18: 240-","journal-title":"Am J Kidney Dis"},{"key":"3878_CR3","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1681\/ASN.V481499","volume":"4","author":"G Appel","year":"1994","unstructured":"Appel G, Pirani C, D'Agati V: Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994, 4: 1499-1515.","journal-title":"J Am Soc Nephrol"},{"key":"3878_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keq395","volume":"50","author":"F Lansigan","year":"2011","unstructured":"Lansigan F, Isufi I, Tagoe CE: Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology. 2011, 50: 824-829. 10.1093\/rheumatology\/keq395.","journal-title":"Rheumatology"},{"key":"3878_CR5","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/art.23662","volume":"58","author":"D Cohen","year":"2008","unstructured":"Cohen D, Koopmans M, Kremer Hovinga IC, Berger SP, Roos van Groningen M, Steup-Beekman GM, de Heer E, Bruijn JA, Bajema IM: Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 2008, 58: 2460-2469. 10.1002\/art.23662.","journal-title":"Arthritis Rheum"},{"key":"3878_CR6","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-","journal-title":"Arthritis Rheum"},{"key":"3878_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/anr.1780320909","volume":"32","author":"MH Liang","year":"1989","unstructured":"Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989, 32: 1107-1118. 10.1002\/anr.1780320909.","journal-title":"Arthritis Rheum"},{"key":"3878_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI: a disease activity index for lupus patients The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640. 10.1002\/art.1780350606.","journal-title":"Arthritis Rheum"},{"key":"3878_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999, 42: 1309-1311. 10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F.","journal-title":"Arthritis Rheum"},{"key":"3878_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/0961203307081340","volume":"16","author":"J Wang","year":"2007","unstructured":"Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L: Induction therapies for Class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 2007, 16: 707-712. 10.1177\/0961203307081340.","journal-title":"Lupus"},{"key":"3878_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005, 353: 2219-2228. 10.1056\/NEJMoa043731.","journal-title":"N Engl J Med"},{"key":"3878_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1191\/0961203305lu2081oa","volume":"14","author":"T Chan","year":"2005","unstructured":"Chan T, Tse K, Tang CSO, Lai K, Li F: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005, 14: 265-272. 10.1191\/0961203305lu2081oa.","journal-title":"Lupus"},{"key":"3878_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/0961203308089408","volume":"17","author":"H Wang","year":"2008","unstructured":"Wang H, Cui T, Hou F, Ni Z, Chen X, Lu F, Xu F, Yu X, Zhang F, Zhao X: Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus. 2008, 17: 638-644. 10.1177\/0961203308089408.","journal-title":"Lupus"},{"key":"3878_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jca.20240","volume":"25","author":"ZM Szczepiorkowski","year":"2010","unstructured":"Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH, Apheresis Applications Committee of the American Society for Apheresis: Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher. 2010, 25: 83-177. 10.1002\/jca.20240.","journal-title":"J Clin Apher"},{"key":"3878_CR15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMoa031855","volume":"350","author":"G Contreras","year":"2004","unstructured":"Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004, 350: 971-980. 10.1056\/NEJMoa031855.","journal-title":"N Engl J Med"},{"key":"3878_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.ki.5001630","volume":"70","author":"C Grootscholten","year":"2006","unstructured":"Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus: Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006, 70: 732-742. 10.1038\/sj.ki.5001630.","journal-title":"Kidney Int"},{"key":"3878_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-3083.2009.02234.x","volume":"69","author":"JJ Zhang","year":"2009","unstructured":"Zhang JJ, Jiang L, Liu G, Wang SX, Zou WZ, Zhang H, Zhao MH: Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol. 2009, 69: 457-464. 10.1111\/j.1365-3083.2009.02234.x.","journal-title":"Scand J Immunol"},{"key":"3878_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ndt\/gfp421","volume":"25","author":"F Yu","year":"2010","unstructured":"Yu F, Tan Y, Zhao MH: Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant. 2010, 25: 145-152. 10.1093\/ndt\/gfp421.","journal-title":"Nephrol Dial Transplant"},{"key":"3878_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004, 65: 521-530. 10.1111\/j.1523-1755.2004.00443.x.","journal-title":"Kidney Int"},{"key":"3878_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ki.1994.70","volume":"45","author":"HA Austin","year":"1994","unstructured":"Austin HA, Boumpas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994, 45: 544-550. 10.1038\/ki.1994.70.","journal-title":"Kidney Int"},{"key":"3878_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ki.1984.75","volume":"25","author":"HA Austin","year":"1984","unstructured":"Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984, 25: 689-695. 10.1038\/ki.1984.75.","journal-title":"Kidney Int"},{"key":"3878_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","volume":"29","author":"GQ Xing","year":"2009","unstructured":"Xing GQ, Chen M, Liu G, Heeringa P, Zhang JJ, Zheng X, Jie E, Kallenberg CG, Zhao MH: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009, 29: 282-291. 10.1007\/s10875-008-9268-2.","journal-title":"J Clin Immunol"},{"key":"3878_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/rheumatology\/kep152","volume":"48","author":"M Galindo","year":"2009","unstructured":"Galindo M, Gonzalo E, Martinez-Vidal MP, Montes S, Redondo N, Santiago B, Loza E, Pablos JL: Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies. Rheumatology. 2009, 48: 1003-1007. 10.1093\/rheumatology\/kep152.","journal-title":"Rheumatology"},{"key":"3878_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0046-8177(85)80212-4","volume":"16","author":"T Tsumagari","year":"1985","unstructured":"Tsumagari T, Fukumoto S, Kinjo M, Tanaka K: Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol. 1985, 16: 43-49. 10.1016\/S0046-8177(85)80212-4.","journal-title":"Hum Pathol"},{"key":"3878_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1191\/0961203302lu224oa","volume":"11","author":"S Vasoo","year":"2002","unstructured":"Vasoo S, Thumboo J, Fong KY: Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus. 2002, 11: 443-450. 10.1191\/0961203302lu224oa.","journal-title":"Lupus"},{"key":"3878_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/ken510","volume":"48","author":"P Letchumanan","year":"2009","unstructured":"Letchumanan P, Ng HJ, Lee LH, Thumboo J: A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology. 2009, 48: 399-403. 10.1093\/rheumatology\/ken510.","journal-title":"Rheumatology"},{"key":"3878_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/0961203310397410","volume":"20","author":"R Silvari\u00f1o","year":"2011","unstructured":"Silvari\u00f1o R, Sant F, Espinosa G, Pons-Estel G, Sol\u00e9 M, Cervera R, Arrizabalaga P: Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011, 20: 721-729. 10.1177\/0961203310397410.","journal-title":"Lupus"},{"key":"3878_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1440-1797.2005.00392.x","volume":"10","author":"S Tang","year":"2005","unstructured":"Tang S, Lui SL, Lai KN: Pathogenesis of lupus nephritis: an update. Nephrology. 2005, 10: 174-179. 10.1111\/j.1440-1797.2005.00392.x.","journal-title":"Nephrology"},{"key":"3878_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11926-004-0046-8","volume":"6","author":"CC Liu","year":"2004","unstructured":"Liu CC, Ahearn JM, Manzi S: Complement as a source of biomarkers in systemic lupus erythematosus: past, present, and future. Curr Rheumatol Rep. 2004, 6: 85-88. 10.1007\/s11926-004-0046-8.","journal-title":"Curr Rheumatol Rep"},{"key":"3878_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/art.1780280810","volume":"28","author":"RM Valentijn","year":"1985","unstructured":"Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, Daha MR, van Es LA: The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1985, 28: 904-913. 10.1002\/art.1780280810.","journal-title":"Arthritis Rheum"},{"key":"3878_CR31","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/ki.1996.460","volume":"50","author":"HE Feucht","year":"1996","unstructured":"Feucht HE, Opelz G: The humoral immune response towards HLA Class II determinants in renal transplantation. Kidney Int. 1996, 50: 1464-1475. 10.1038\/ki.1996.460.","journal-title":"Kidney Int"},{"key":"3878_CR32","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/0961203310368409","volume":"19","author":"Y Shen","year":"2010","unstructured":"Shen Y, Chen X, Sun C, Dai M, Yan Y, Yang C: Association between anti-\u03b22 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus. 2010, 19: 1195-1203. 10.1177\/0961203310368409.","journal-title":"Lupus"},{"key":"3878_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/0961203307083279","volume":"16","author":"S Li","year":"2007","unstructured":"Li S, Liu Z, Zen C, Wang Q, Wang Y, Li L: Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection. Lupus. 2007, 16: 875-880. 10.1177\/0961203307083279.","journal-title":"Lupus"},{"key":"3878_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","volume":"164","author":"H Watanabe","year":"2000","unstructured":"Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS: Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000, 164: 786-","journal-title":"J Immunol"},{"key":"3878_CR35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1177\/0961203311415561","volume":"20","author":"N Sato","year":"2011","unstructured":"Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, Toki A, Horikoshi S, Ohi H, Matsushita M: Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011, 20: 1378-1386. 10.1177\/0961203311415561.","journal-title":"Lupus"},{"key":"3878_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/BF00915156","volume":"8","author":"M Brai","year":"1988","unstructured":"Brai M, Misiano G, Maringhini S, Cutaja I, Hauptmann G: Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. J Clin Immunol. 1988, 8: 50-56. 10.1007\/BF00915156.","journal-title":"J Clin Immunol"},{"key":"3878_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s002510050631","volume":"51","author":"P S\u00e1nchez-Corral","year":"2000","unstructured":"S\u00e1nchez-Corral P, Bellavia D, Amico L, Brai M, Rodr\u00edguez de C\u00f3rdoba S: Molecular basis for factor H and FHL-1 deficiency in an Italian family. Immunogenetics. 2000, 51: 366-369. 10.1007\/s002510050631.","journal-title":"Immunogenetics"},{"key":"3878_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1046\/j.1365-3083.2001.00931.x","volume":"53","author":"N Amadei","year":"2001","unstructured":"Amadei N, Baracho G, Nudelman V, Bastos W, Florido M, Isaac L: Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand J Immunol. 2001, 53: 615-621. 10.1046\/j.1365-3083.2001.00931.x.","journal-title":"Scand J Immunol"},{"key":"3878_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1681\/ASN.2010060647","volume":"22","author":"L Bao","year":"2010","unstructured":"Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2010, 22: 285-295.","journal-title":"J Am Soc Nephrol"},{"key":"3878_CR40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/eji.1830210337","volume":"21","author":"C Estaller","year":"1991","unstructured":"Estaller C, Weiss EH, Schwaeble W, Dierich M: Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur J Immunol. 1991, 21: 799-802. 10.1002\/eji.1830210337.","journal-title":"Eur J Immunol"},{"key":"3878_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y: Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res. 2009, 66: 336-340. 10.1203\/PDR.0b013e3181b1bd4a.","journal-title":"Pediatr Res"},{"key":"3878_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1681\/ASN.2005080868","volume":"17","author":"M J\u00f3zsi","year":"2006","unstructured":"J\u00f3zsi M, Heinen S, Hartmann A, Ostrowicz CW, H\u00e4lbich S, Richter H, Kunert A, Licht C, Saunders RE, Perkins SJ: Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol. 2006, 17: 170-177.","journal-title":"J Am Soc Nephrol"},{"key":"3878_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semnephrol.2006.09.009","volume":"27","author":"L Bao","year":"2007","unstructured":"Bao L, Quigg RJ: Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 2007, 27: 69-80. 10.1016\/j.semnephrol.2006.09.009.","journal-title":"Semin Nephrol"},{"key":"3878_CR44","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","volume":"177","author":"K Ritis","year":"2006","unstructured":"Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD: A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006, 177: 4794-4802.","journal-title":"J Immunol"},{"key":"3878_CR45","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","volume":"110","author":"P Redecha","year":"2007","unstructured":"Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G: Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood. 2007, 110: 2423-2431. 10.1182\/blood-2007-01-070631.","journal-title":"Blood"},{"key":"3878_CR46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s004670050029","volume":"14","author":"A Citak","year":"2000","unstructured":"Citak A, Emre S, S\u00e2irin A, Bilge I, Nayir A: Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000, 14: 138-142. 10.1007\/s004670050029.","journal-title":"Pediatr Nephrol"},{"key":"3878_CR47","first-page":"346","volume":"11","author":"T Hara","year":"2005","unstructured":"Hara T, Naito K: Inherited antithrombin deficiency and end stage renal disease. Med Sci Monit. 2005, 11: 346-354.","journal-title":"Med Sci Monit"},{"key":"3878_CR48","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","volume":"52","author":"SS Pierangeli","year":"2005","unstructured":"Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005, 52: 2120-2124. 10.1002\/art.21157.","journal-title":"Arthritis Rheum"},{"key":"3878_CR49","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1681\/ASN.V94590","volume":"9","author":"M Nangaku","year":"1998","unstructured":"Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Morgan B, Johnson RJ, Couser WG: CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol. 1998, 9: 590-597.","journal-title":"J Am Soc Nephrol"},{"key":"3878_CR50","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P: Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med. 2011, 364: 2561-2563. 10.1056\/NEJMc1100859.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4142\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:50:05Z","timestamp":1728370205000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,2]]}},"alternative-id":["3878"],"URL":"https:\/\/doi.org\/10.1186\/ar4142","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]},"assertion":[{"value":"20 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R12"}}